Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J. Short, Farhad Ravandi, Guillermo Montalban‐Bravo et al.|Journal of Clinical Oncology|2024Cited by 161
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLHagop M. Kantarjian, Elias Jabbour, Nicholas J. Short et al.|Journal of Clinical Oncology|2024Cited by 81
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J. Short, Hagop M. Kantarjian, Muharrem Müftüoğlu et al.|Journal of Hematology & Oncology|2023Cited by 52
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemiaNicholas J. Short, Hagop Kantarjian, Elias Jabbour et al.|Blood Advances|2024Cited by 35